




Cyrus Poonawalla Group

212/2 Hadapsar, Pune 411 028, India. Tel.: +91 20 26993900/04 Fax: +91 20 26993924.
E-mail: business@seruminstitute.com

www.seruminstitute.com



Protection from birth onwards



One of the
WORLD'S LARGEST
vaccine manufacturers by
number of doses produced.



Mr. Adar C. Poonawalla
C.E.O.

“It is our endeavour to make quality vaccines more affordable around the world because we firmly believe that good health should be the right of every child.”

Dr. Cyrus S. Poonawalla,
Chairman and Managing Director



Overview

1 India’s No.1 biotechnology company

1.6 bn Vaccine doses sold globally per year

170 Countries to which our vaccines are supplied

20+ WHO pre-qualified vaccines; Highest vaccine presentations in the world for a single manufacturer

2 International acquisitions; Bilthoven Biologicals (Netherlands) & Praha Vaccines (Czech Republic)



Milestones over 5 decades

In association with...

WHO | UNICEF | PAHO | Gavi | PATH | Bill & Melinda Gates foundation

1974
Commenced production of **DTP Vaccine**



1967
Operations began with manufacture of **Tetanus Antitoxin** followed by **Tetanus Toxoid**

1989
M-VAC (Measles Vaccine)



1981
Polyvalent Anti-Snake Venom Serum (Asia)

1993
First vaccine Pre-qualified by World Health Organization (**WHO**) and launch of **TRESIVAC** (MMR Vaccine)



1991
Polyvalent Anti-Snake Venom Serum (Africa)

2002
Sii TUBERVAC (BCG Vaccine)



2001
GENEVAC B (Hepatitis B Vaccine (rdNA))

2005
Q-VAC (DTP-HepB Combination Vaccine)



2004
Sii RABIVAX (The world's only adsorbed liquid HDC Rabies Vaccine)

2008
PENTAVAC (Combi-pack of Pentavalent Vaccine (DTP-HepB+Hib)) and **QUADROVAX** (Quadrivalent Vaccine (DTP+Hib))



2007
HIB PRO (Hib Vaccine) and **ONCO-BCG** (BCG Vaccine for Bladder Cancer)

2010
NASOVAC (H1N1 Influenza Vaccine), **ENZAVAC** (H1N1 Influenza Vaccine inactivated), **MenAfriVac** (Meningococcal A conjugate vaccine) and **REPOITIN** (r-HuEPO)



2009
PENTAVAC SD/PFS (Liquid Pentavalent Vaccine (DTP-HepB-Hib))

2012
Made first overseas acquisition, **Bilthoven Biologicals, Netherlands**. Launched **NASOVAC-S** (Trivalent seasonal influenza vaccine)



2011
POLIOVAC PFS (Inactivated polio vaccine)

2017
Made second overseas acquisition, **Praha Vaccines, Czech Republic** Launching **Tresivac NF** (India's first needle free MMR vaccine), **Rotasiil** (First thermostable Rotavirus Vaccine), **RABISHIELD** (World's first Rabies Human Monoclonal antibody, recombinant), **RABIVAX-S Vero-cell** (Rabies vaccine Human I.P.).



2014
OPV (Oral Polio Vaccine)



 **SERUM INSTITUTE OF INDIA**
Cyrus Poonawalla Group

“Saving the lives of millions of children across the globe.”

Intensive R&D – creating solutions for tomorrow

Our R&D initiatives include development of better adjuvants, heat stable vaccines, conjugate vaccines, monoclonal antibodies and others by using cutting edge genetic and cell based technologies. We constantly strive on improving the methods of vaccine delivery for our vaccines viz. use of jet injectors. Furthermore, there is an extensive range of vaccines in the development pipeline undergoing various stages of testing and clinical evaluation.

High quality pre-clinical and clinical research are performed in compliance with GLP and GCP guidelines on all products before they are marketed worldwide. After licensure, a diligent pharmacovigilance is maintained as per international norms.

“Our R&D efforts are focused on developing vaccines that will meet the specific needs of different segments of the global population.”



State-of-the-Art Production Facilities

“We have the most modern laboratories with high-tech machinery and computerized equipment for the production of our life saving biologicals.”



Serum Institute has large bio-reactors for manufacturing and lyophilisation facilities of parenterals which are state-of-the-art and comply with BSL-2 and BSL-2+ standards. Equipment providing Class 100 and Class 10,000 conditions are also electronically controlled.

We have sophisticated, high resolution, electronically controlled screeners to inspect products for any minute particulate matter undetectable to the normal human eye. Our sophisticated machines are capable of working at high speeds and have been installed with filling accuracy to the third digit decimal point to ensure accuracy and consistency.

The production facilities are continuously upgraded to ensure compliance with cGMP regulations and have been accredited by WHO, Geneva.



Commitment to Quality

Our quality control laboratories are equipped with a wide array of sophisticated analytical equipment. In addition, each of our manufacturing facilities have their own laboratories to perform various quality control and assurance tests. While strict adherence to cGMP norms and SOPs ensures consistent quality for all batches, regular training of our personnel keeps us updated with the latest advances in production & quality testing standards.

Numerous product approvals from WHO and national & international regulatory authorities stand as testimony of our commitment to quality. Producing high quality vaccine necessitates unrelenting & detailed Quality Assurance which is guaranteed by following quality systems & frequent audits.



“Emphasis on quality without compromise is ingrained in our work culture and constant modernization of equipment ensures high quality standards.”



Product List

- BACTERIAL VACCINES**
- Diphtheria-Tetanus-Pertussis (DTwP) Vaccine
1 dose, 10 dose, 20 dose
 - Diphtheria and Tetanus (Td) Vaccine for Adults and Adolescents
1 dose, 10 dose, 20 dose
 - Diphtheria and Tetanus (DT) Vaccine (Pediatric)
1 dose, 10 dose, 20 dose
 - Diphtheria and Tetanus (DT) Vaccine (Pediatric) (Thiomersal Free)
1 dose
 - Tetanus Toxoid (TT) Vaccine
1 dose, 10 dose, 20 dose
 - BCG Vaccine
10 dose, 20 dose

- VIRAL VACCINES**
- Measles Vaccine
1 dose, 2 dose, 5 dose, 10 dose
 - Rubella Vaccine
1 dose, 2 dose, 5 dose, 10 dose
 - Measles, Mumps and Rubella (MMR) Vaccine
1 dose, 2 dose, 5 dose, 10 dose
 - Measles and Rubella (MR) Vaccine
1 dose, 2 dose, 5 dose, 10 dose
 - Hepatitis B Vaccine (Pediatric/Adult)
1 dose, 10 dose
 - Hepatitis B Vaccine (Pediatric/Adult) (Thiomersal Free)
1 dose
 - RABIVAX-S
Rabies Vaccine (lyophilised)
1 dose
 - ROTASIIL
Rotavirus Vaccine (lyophilised)
1 dose, 2 dose
 - Poliomyelitis Vaccine (Inactivated)
1 dose, 2 dose, 5 dose
 - Poliomyelitis Vaccine (Oral)
Bivalent type 1 and 3
1ml - 10 dose, 2ml - 20 dose

- COMBINATION VACCINES**
- Diphtheria, Tetanus, Pertussis and Hepatitis B (DTwPHB) Vaccine
1 dose, 10 dose
 - Diphtheria, Tetanus, Pertussis and Haemophilus influenzae Type b Conjugate (DTwPHib) Vaccine
1 dose

Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae Type b Conjugate (Penta) Vaccine
1 dose, 10 dose

POLYSACCHARIDE CONJUGATE VACCINES

Haemophilus influenzae Type b Conjugate Vaccine
1 dose

MenAfriVac
Meningococcal A Conjugate Vaccine (lyophilised)
(5mcg, 10mcg) 10 dose

INFLUENZA VACCINE

NASOVAC-S
Influenza Vaccine Seasonal trivalent (Intranasal)
1 dose

ANTI SERA

Tetanus Antitoxin 1500 IU, 3000 IU, 20000 IU

URO-ONCOLOGY

ONCO-BCG (BCG LIVE) 40 mg/ml

RECOMBINANT PRODUCTS

REPOITIN (Vial)
Erythropoietin Injection B.P.
1000 IU, 2000 IU, 3000 IU, 4000 IU, 6000 IU, 8000 IU, 10000 IU

REPOITIN (PFS)
Erythropoietin Injection B.P.
1000 IU, 2000 IU, 3000 IU, 4000 IU, 6000 IU, 8000 IU, 10000 IU

RABISHIELD
Rabies Human Monoclonal Antibody
100 IU, 250 IU

PIPELINE PRODUCTS

Tdap Vaccine
Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W-135, X)
Pneumococcal Conjugate Vaccine
HPV vaccine
Rotavirus vaccine (Liquid)
Recombinant BCG vaccine
ErepoXen (Polysialylated Erythropoietin)
Dengue vaccine
Dengue Monoclonal Antibody

Major Achievements



“Serum Institute of India has demonstrated unparalleled focus in supplying several hundred million doses of its Measles and Rubella Vaccines to curb the scourge of Rubella and Measles to 38 regions in America, for the past 16 years, for routine immunization as well as for mass campaigns. The contribution of Serum Institute has been recognized in a true sense, since the region of Americas have showed no recorded cases of endemic Rubella since February 2010.”

The Pan American Health Organization (PAHO) and the Pan American Health and Education Foundation (PAHEF) presented Dr. Cyrus S. Poonawalla with the award for 'Excellence in Inter-American Public Health', making him the **first Indian** to get this prestigious award at the hands of Dr. Mirta Roses Periago for his extraordinary contribution to eliminate Rubella and Congenital Rubella Syndrome in America, on 28th September 2010, Washington D.C., USA.

From right-Dr. Mirta Roses Periago, Director – PAHO, Dr. Jose A. Cordova Villalobos, Secretary of Health (Mexico), Dr. Cyrus S. Poonawalla and Dr. Jon Andrus, Deputy Director – PAHO.



Dr. Cyrus S. Poonawalla receiving the **Sabin Humanitarian Award and Sabin Global Corporate Philanthropy Award** at the University Club in New York, U.S.A., on 29th June 2005 at the hands of Dr. Seth Berkley, President, International AIDS Vaccine Initiative (Associate Bill Gates Foundation) and the current President of GAVI (Global Alliance for Vaccine & Immunization).

Late Dr. APJ Abdul Kalam, Hon. President of India presenting the '**Padmashree**' award to Dr. Cyrus S. Poonawalla on 28th March 2005 at Rashtrapati Bhawan, New Delhi.



Notable Dignitaries at Serum



Hon'ble Prime Minister of India, Shri. Narendra Modi understanding from Dr. Cyrus S. Poonawalla the facilities and impact of “Make in India” vaccine used globally, manufactured by Serum Institute of India on the occasion of PM’s visit on 13th November 2016.




“This is an amazing company, and its facilities would be considered state of the art anywhere in the world. Serum produces low cost, high quality vaccines used in 140 countries around the world.”
“Serum's work has dramatically lowered the cost of Pentavalent vaccines (and a great many others) and is a true contribution by India to the well-being of the world.”

Mr Bill Gates (centre), co-founder of the Bill & Melinda Gates Foundation with Dr Cyrus S. Poonawalla (left) and Mr Adar C. Poonawalla (right) during his visit to the Serum Institute of India at Pune on 31st May 2012.



His Royal Highness Prince of Wales (center) being explained the Laboratory Sites during his visit to Serum Institute of India with Dr. Cyrus S. Poonawalla (right) and Mr. Adar C. Poonawalla (left) on 10th November 2013.

Dr. Jonas Salk, inventor of the injectable Polio Vaccine at Serum Institute of India. From left : Dr. Jonas Salk, Dr. Cyrus S. Poonawalla and Dr. Jal Mehta.



Corporate Social Responsibilities (CSR)

Adar Poonawalla Clean City is an INR 1 Billion environmentally sustainable initiative with an objective to provide Indian urban citizens a healthier life through able management & local government support. This initiative addresses the urban challenge of wet waste management and has a fleet of specially designed trucks, thousands of trash bins and a slew of garbage processing plants.

The multispeciality Viloo Poonawalla Memorial Hospital in Pune provides special attention to people below poverty line with quality treatments at affordable rates. Furthermore, we have often supplied various vaccines free of cost or at subsidized prices to benefit global & national masses. We at Serum Institute also have a Leprosy Rehabilitation Center for accommodation and training of Leprosy cured handicapped persons enabling them to support themselves and live a dignified life.

We believe that education is important, especially for the underprivileged and thus have constructed and supported 5 English medium schools in tier 2 cities of India.

Measures have been undertaken to reduce the company’s carbon footprint by ensuring a reduction in GHG emissions by installing 57.2 MW wind power projects utilizing the available wind energy. Currently almost 85% of our energy requirements are met by wind power.

A pilot plant providing 2 million liters of drinking water per day with a plan to increase this to 10 million liters has been commissioned to provide clean drinking water to those who do not have access to clean potable water in Pune city. We also recycle about 65% of waste water to achieve better water efficiency.

Serum Institute of India has also contributed towards several projects like widening and asphaltting of roads, constructing public toilets and bridges, developing and maintaining gardens and also playgrounds to improve the quality of life of the local population.

“We recognize the importance of having a sustainable social, environmental and economic development that not only provides a healthier environment but also helps the citizens to thrive and achieve their goals”



Clean Drinking Water Plant, Pune, India



Viloo Poonawalla Memorial Hospital, Pune, India



Towards 100% Green energy generation

